GO
Loading...

Australia's Sigma Says Discussing Symbion Bid

Australian drugs company Sigma Pharmaceuticals said on Wednesday it was in final talks with a potential partner on a counter bid for Symbion Health before a deadline of June 19.

Sigma Chief Executive Elmo de Alwis told Reuters that the company had narrowed down a list of potential partners to an Australian private equity firm, which he declined to name. The two were discussing a cash bid for Symbion in a structure that would appease regulatory concerns.

"The structure would be that we would buy what we needed and they would buy what they needed. We couldn't buy the (drugs) wholesaling part for example because there would be (competition) issues," said de Alwis.

Symbion has accepted a A$2.8 billion (US$2.4 billion) takeover bid led by Australian hospital operator Healthscope and has given rival bidders until June 19 to make an offer.

Sigma wants Symbion's consumer and pharmacy divisions, which account for about one third of Symbion's earnings. Healthscope's private equity bid partners, Ironbridge Capital and Archer Capital, have valued the divisions at A$1.043 billion.

"The valuation details haven't been finalized but Symbion has specified that for them to consider the offer, (the bid for the consumer and pharmacy divisions) has to be about A$1.075 billion," de Alwis said.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More*

Don't Miss

U.S. Video

  • CNBC's Tyler Mathisen looks back at the week's top business and financial stories. The markets were closed for Thanksgiving, but did manage to hit new highs. Low oil prices gave consumers more money to spend for Black Friday.

  • Cyber Monday deals on Walmart's website on Dec. 2, 2013.

    CNBC's Tyler Mathisen looks ahead to what are likely to be next week's top stories. The jobs report comes out this week, as do auto sales. And the Rockefeller Center Christmas tree is lit.

  • Following last week's wild energy ride, analysts expect oil prices to continue to drop during the holiday season. CNBC's Patti Domm reports.